3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
20
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
7
Skin Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Colorectal Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Leukemia, Lymphocytic, Chronic, B-Cell
5
Uveal Melanoma
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Follicular
3
Lymphoma
3
Lung Neoplasms
3
Leukemia
3
Esophageal Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Interleukin-2
×
1 year
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled